Cite
Kulkarni PS, Padmapriyadarsini C, Vekemans J, et al. A phase 2/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in India. EClinicalMedicine. 2021;42:101218doi: 10.1016/j.eclinm.2021.101218.
Kulkarni, P. S., Padmapriyadarsini, C., Vekemans, J., Bavdekar, A., Gupta, M., Kulkarni, P., Garg, B. S., Gogtay, N. J., Tambe, M., Lalwani, S., Singh, K., Munshi, R., Meshram, S., Selvavinayagam, T. S., Pandey, K., Bhimarasetty, D. M., Ramakrishnan, S. R., Bhamare, C., Dharmadhikari, A., Vadakkedath, R., Bonhomme, C. J., Thakar, M., Kurle, S. N., Kelly, E. J., Gautam, M., Gupta, N., Panda, S., Bhargava, B., Shaligram, U., Kapse, D., Gunale, B. (2021). A phase 2/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in India. EClinicalMedicine, 42101218. https://doi.org/10.1016/j.eclinm.2021.101218
Kulkarni, Prasad S, et al. "A phase 2/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in India." EClinicalMedicine vol. 42 (2021): 101218. doi: https://doi.org/10.1016/j.eclinm.2021.101218
Kulkarni PS, Padmapriyadarsini C, Vekemans J, Bavdekar A, Gupta M, Kulkarni P, Garg BS, Gogtay NJ, Tambe M, Lalwani S, Singh K, Munshi R, Meshram S, Selvavinayagam TS, Pandey K, Bhimarasetty DM, Ramakrishnan SR, Bhamare C, Dharmadhikari A, Vadakkedath R, Bonhomme CJ, Thakar M, Kurle SN, Kelly EJ, Gautam M, Gupta N, Panda S, Bhargava B, Shaligram U, Kapse D, Gunale B. A phase 2/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in India. EClinicalMedicine. 2021 Dec;42:101218. doi: 10.1016/j.eclinm.2021.101218. Epub 2021 Nov 30. PMID: 34870133; PMCID: PMC8629682.
Copy
Download .nbib